logo
Plus   Neg
Share
Email

Novartis: Cosentyx Shows Long-lasting Efficacy In FUTURE 5 Trial - Quick Facts

Novartis (NVS) said new data from the FUTURE 5 trial demonstrated that 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose) of psoriatic arthritis patients treated with Cosentyx found no radiographic progression at 2 years. Clinical responses were also maintained throughout the duration of the study.

FUTURE 5 is a Phase III, randomized, double-blind, placebo-controlled study evaluating Cosentyx on radiographic progression across 2 years in PsA patients. In the study, 996 adults with active PsA were randomized to receive subcutaneous Cosentyx 300 mg.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple chief executive officer Tim Cook condemned the killing of an unarmed black man, George Floyd, and called for the creation of a "better, more just world for everyone," according to reports citing a memo to employees. Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining.
Follow RTT